Literature DB >> 25268545

Comparison of the effects of PRKAR1A and PRKAR2B depletion on signaling pathways, cell growth, and cell cycle control of adrenocortical cells.

F Basso1, F Rocchetti1, S Rodriguez1, M Nesterova2, F Cormier1, C A Stratakis2, B Ragazzon1, J Bertherat1, M Rizk-Rabin1.   

Abstract

The cyclic AMP/protein kinase A signaling cascade is one of the main pathways involved in the pathogenesis of adrenocortical tumors. The PKA R1A and R2B proteins are the most abundant regulatory subunits in endocrine tissues. Inactivating mutations of PRKAR1A are associated with Carney complex and a subset of sporadic tumors and the abundance of R2B protein is low in a subset of secreting adrenocortical adenomas. We previously showed that PRKAR1A and PRKAR2B inactivation have anti-apoptotic effects on the adrenocortical carcinoma cell line H295R. The aim of this study was to compare the effects of PRKAR1A and PRKAR2B depletion on cell proliferation, apoptosis, cell signaling pathways, and cell cycle regulation. We found that PRKAR2B depletion is compensated by an upregulation of R1A protein, whereas PRKAR1A depletion has no effect on the production of R2B. The depletion of either PRKAR1A or PRKAR2B promotes the expression of Bcl-xL and resistance to apoptosis; and is associated with a high percentage of cells in S and G2 phase, activates PKA and MEK/ERK pathways, and impairs the expression of IkB leading to activate the NF-κB pathway. However, we observed differences in the regulation of cyclins. The depletion of PRKAR1A leads to the accumulation of cyclin D1 and p27kip, whereas the depletion of PRKAR2B promotes the accumulation of cyclin A, B, cdk1, cdc2, and p21Cip. In conclusion, although the depletion of PRKAR1A and PRKAR2B in adrenocortical cells has similar effects on cell proliferation and apoptosis; loss of these PKA subunits differentially affects cyclin expression. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25268545      PMCID: PMC4727442          DOI: 10.1055/s-0034-1389951

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  20 in total

1.  Protein kinase A effects of an expressed PRKAR1A mutation associated with aggressive tumors.

Authors:  Elise Meoli; Ioannis Bossis; Laure Cazabat; Manos Mavrakis; Anelia Horvath; Sotiris Stergiopoulos; Miriam L Shiferaw; Glawdys Fumey; Karine Perlemoine; Michael Muchow; Audrey Robinson-White; Frank Weinberg; Maria Nesterova; Yianna Patronas; Lionel Groussin; Jérôme Bertherat; Constantine A Stratakis
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

2.  8Cl-cAMP modifies the balance between PKAR1 and PKAR2 and modulates the cell cycle, growth and apoptosis in human adrenocortical H295R cells.

Authors:  Zhor Bouizar; Bruno Ragazzon; Lucie Viou; Mariuccia Hortane; Jerôme Bertherat; Marthe Rizk-Rabin
Journal:  J Mol Endocrinol       Date:  2010-03-17       Impact factor: 5.098

3.  A-kinase-interacting protein 1 (AKIP1) acts as a molecular determinant of PKA in NF-kappaB signaling.

Authors:  Nan Gao; Yurina Hibi; Marni Cueno; Kaori Asamitsu; Takashi Okamoto
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

Review 4.  How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues?

Authors:  Madson Q Almeida; Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2010-11-25       Impact factor: 4.102

5.  Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome.

Authors:  Felix Beuschlein; Martin Fassnacht; Guillaume Assié; Davide Calebiro; Constantine A Stratakis; Andrea Osswald; Cristina L Ronchi; Thomas Wieland; Silviu Sbiera; Fabio R Faucz; Katrin Schaak; Anett Schmittfull; Thomas Schwarzmayr; Olivia Barreau; Delphine Vezzosi; Marthe Rizk-Rabin; Ulrike Zabel; Eva Szarek; Paraskevi Salpea; Antonella Forlino; Annalisa Vetro; Orsetta Zuffardi; Caroline Kisker; Susanne Diener; Thomas Meitinger; Martin J Lohse; Martin Reincke; Jérome Bertherat; Tim M Strom; Bruno Allolio
Journal:  N Engl J Med       Date:  2014-02-26       Impact factor: 91.245

6.  Identification of a clinically homogenous subgroup of benign cortisol-secreting adrenocortical tumors characterized by alterations of the protein kinase A (PKA) subunits and high PKA activity.

Authors:  C Vincent-Dejean; L Cazabat; L Groussin; K Perlemoine; G Fumey; F Tissier; X Bertagna; J Bertherat
Journal:  Eur J Endocrinol       Date:  2008-06       Impact factor: 6.664

7.  Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells.

Authors:  Bruno Ragazzon; Laure Cazabat; Marthe Rizk-Rabin; Guillaume Assie; Lionel Groussin; Hélène Fierrard; Karine Perlemoine; Antoine Martinez; Jérôme Bertherat
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

8.  The rate of NF-κB nuclear translocation is regulated by PKA and A kinase interacting protein 1.

Authors:  Charles C King; Mira Sastri; Philip Chang; Juniper Pennypacker; Susan S Taylor
Journal:  PLoS One       Date:  2011-04-27       Impact factor: 3.240

9.  Disruption of protein kinase A in mice enhances healthy aging.

Authors:  Linda C Enns; John F Morton; Piper R Treuting; Mary J Emond; Norman S Wolf; Dao-Fu Dai; G S McKnight; Peter S Rabinovitch; Warren C Ladiges
Journal:  PLoS One       Date:  2009-06-18       Impact factor: 3.240

10.  Frequent engagement of RelB activation is critical for cell survival in multiple myeloma.

Authors:  Françoise Cormier; Hélène Monjanel; Claire Fabre; Katy Billot; Elène Sapharikas; Fanny Chereau; Didier Bordereaux; Thierry J Molina; Hervé Avet-Loiseau; Véronique Baud
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

View more
  6 in total

Review 1.  A genetic and molecular update on adrenocortical causes of Cushing syndrome.

Authors:  Maya Lodish; Constantine A Stratakis
Journal:  Nat Rev Endocrinol       Date:  2016-03-11       Impact factor: 43.330

2.  PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer.

Authors:  Jianjun Sha; Wei Xue; Baijun Dong; Jiahua Pan; Xiaorong Wu; Dong Li; Dongming Liu; Yiran Huang
Journal:  Oncotarget       Date:  2017-01-24

3.  Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.

Authors:  Sida Liao; Ophélia Maertens; Karen Cichowski; Stephen J Elledge
Journal:  Genes Dev       Date:  2018-08-22       Impact factor: 11.361

4.  diaPASEF Proteomics and Feature Selection for the Description of Sputum Proteome Profiles in a Cohort of Different Subtypes of Lung Cancer Patients and Controls.

Authors:  María Del Sol Arenas-De Larriva; Alejandro Fernández-Vega; Bernabe Jurado-Gamez; Ignacio Ortea
Journal:  Int J Mol Sci       Date:  2022-08-05       Impact factor: 6.208

5.  Hypoxia and the hypoxia inducible factor 1α activate protein kinase A by repressing RII beta subunit transcription.

Authors:  Kristin Lucia; Yonghe Wu; Jose Monteserin Garcia; Anne Barlier; Michael Buchfelder; Wolfgang Saeger; Ulrich Renner; Günter K Stalla; Marily Theodoropoulou
Journal:  Oncogene       Date:  2020-02-28       Impact factor: 9.867

6.  p53 and ANXA4/NF‑κB p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma.

Authors:  Juanjuan Liu; Huimin Wang; Mingjun Zheng; Lu Deng; Xue Zhang; Bei Lin
Journal:  Int J Mol Med       Date:  2020-10-14       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.